SESSION 1 | 14:03 – 15:17
Innovation in Treatment Modalities (I)
Moderators: Anat Loewenstein/ Kourous Rezaei
14:03
Sascha Fauser: Roche — Innovation in large molecules
14:11
Sergio Leal: Bayer — Bayer’s vision for the future of ophthalmology
14:19
Mathias Schifflers: Abbvie — A commitment to addressing unmet needs in eye care disease
14:27
Ramin Valian: Abbvie — AbbVie/REGENXBIO-314: One-time gene therapy for the treatment of degenerative diseases of the retina
14:35
Laurent Fischer: Adverum — Beyond Vabysmo and EyleaHD – Is innovation needed in wet AMD?
14:43
Robert Kim: 4D Molecular Therapeutics — Intravitreal AAV retinal gene therapy
14:51
Kerstin Wickstrom: Icelandic Medicines Agency (virtual) — Development and validation of biomarkers and surrogate endpoints. A regulatory view
14:59 – 15:17: Panel Discussion
Megan Baldwin: Ophthea
Chris Brittain: Roche/Genentech
Victor Chong: Janssen
Thomas Ciulla: Clearside Therapeutics
George Elston: EyePoint Pharmaceuticals
Jane Moseley: EMA
